Apitegromab for spinal muscular atrophies of childhood

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 14 Dec 2021: Trial registered, NCT05156320
  2. 14 Apr 2022: Trial started, NCT05156320
  3. 25 Nov 2022: Trial registered, NCT05626855
  4. 17 Apr 2023: Trial started, NCT05626855

The trials

NCT03921528: An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy

State
Completed
Phase
Phase 2
People
58 taking part
Started
22 Apr 2019
Primary completion
19 Jan 2021
Arms
Cohort 1, Cohort 2, Cohort 3
Results
Posted on the registry
Papers
doi:10.1212/wnl.0000000000209151
  1. 19 Apr 2019: Trial registered
  2. 22 Apr 2019: Trial started
  3. 17 Nov 2022: Trial results posted
  4. 28 Feb 2024: Trial completed

NCT05156320: Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

State
Completed
Phase
Phase 3
People
188 taking part
Started
14 Apr 2022
Primary completion
18 Dec 2024
Arms
Main Efficacy Population (Apitegromab 10 mg/kg), Main Efficacy Population (Apitegromab 20 mg/kg), Exploratory Subpopulation (Apitegromab)
Results
None posted
Papers
doi:10.1016/s1474-4422(25)00225-x
  1. 14 Dec 2021: Trial registered
  2. 14 Apr 2022: Trial started
  3. 18 Dec 2024: Trial completed

NCT05626855: Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

State
Under way
Phase
Phase 3
People
238 taking part
Started
17 Apr 2023
Primary completion
1 Nov 2026
Arms
Treatment Period
Results
None posted
  1. 25 Nov 2022: Trial registered
  2. 17 Apr 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.